A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Apr 2015 Status changed from active, no longer recruiting to completed,as reported by ClinicalTrials.gov.
- 22 Dec 2014 Planned End Date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.